Side effect analysis and nursing for childhood malignant patients who received in-vitro amplification HLA-haploidentical donor immune cell infusions
10.3760/cma.j.issn.1672-7088.2013.31.019
- VernacularTitle:儿童恶性肿瘤患者接受体外扩增HLA-半相合供者免疫细胞输注的不良反应分析及护理
- Author:
Ruiqing CAI
;
Caifen PENG
;
Shaomin QIN
;
Meiling LIU
- Publication Type:Journal Article
- Keywords:
Childhood malignant patients;
HLA-haploidentical donor cells;
Side effects;
Nursing
- From:
Chinese Journal of Practical Nursing
2013;29(31):36-39
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the side effects of in-vitro amplification human leukocyte antigen (HLA)-haploidentical donor immune cell infusion(HDICI) in childhood malignant patients,and to provide the basis for how to nurse these patients.Methods From September 2011 to September 2012,twelve hospitalized childhood malignant patients were recruited in Cancer Center of Sun Yat-sen University,and they received a total of 92 times of HDICIs for immunotherapy.Side effects were carefully observed both during and 2 hours and 24 hours after each infusion,and we also provided psychological nursing,pre-infusion nursing,side effect analysis and corresponding care during infusion,post-infusion education and follow-up for every childhood patient.Results Among 92 times of HDICIs,fever occurred in 20 cases,of whom 6 cases were with chills,1 case with febrile convulsion,all achieved remission after receiving symptomatic treatment.5 cases were also recorded with a slight change of mood.Vital signs were all stable both during and after every HDICIs; and no nausea,vomiting,abdominal pain,diarrhea,rash,swelling or allergic reaction was observed.Neither change of the hemogram nor biochemical indexes was recorded before or after every course of HDICI.Conclusions Our study showed that HDICIs for immunotherapy in childhood malignant patients were safe,and during the whole infusions,much attention should be paid both for psychological nursing,pre-infusion anti-anaphylactic treatment,temperature monitoring,discovery of the precursor of febrile convulsion promptly,symptomatic treatment against corresponding side effects,and post-infusion education and follow-up,all those above are of great importance for childhood malignant patients who received HDICIs for immunotherapy successfully.
